Crossmark

Phase I trial of HuMax-IL8 (BMS-986253), an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors

Crossref DOI link: https://doi.org/10.1186/s40425-019-0706-x

Published Online: 2019-09-05

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Bilusic, Marijo

Heery, Christopher R.

Collins, Julie M.

Donahue, Renee N.

Palena, Claudia

Madan, Ravi A.

Karzai, Fatima

Marté, Jennifer L.

Strauss, Julius

Gatti-Mays, Margaret E.

Schlom, Jeffrey

Gulley, James L. https://orcid.org/0000-0002-6569-2912
Funding

Funding for this research was provided by:

National Cancer Institute
License Information

Text and Data Mining valid from 2019-09-05
More Information

Article History

Received: 9 April 2019

Accepted: 7 August 2019

First Online: 5 September 2019

Ethics approval and consent to participate

: All patients gave written informed consent for participation. This study was approved by the National Cancer Institute Institutional Review Board. The trial national registration number is NCT02536469.

: Not applicable.

: All National Cancer Institute authors declare that they have no competing interests.Dr. Heery is an employee of Precision Biosciences and has no financial relationship with BMS or this product.No writing assistance was utilized in the production of this manuscript.